Drug packaging

West to Present on Development of Large Volume Delivery Systems, Self-injection Devices, and Prefillable Syringe Component Expertise at the PDA Conference

Retrieved on: 
Lunedì, Ottobre 16, 2023
Universe, WST, Product management, Syringe, NYSE, West Pharmaceutical Services, Conference, PDA, Drug packaging, Medical device

EXTON, Pa., Oct. 16, 2023 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced participation in the 2023 PDA Universe of Pre-Filled Syringes and Injection Devices Conference in Gothenburg, Sweden to showcase its leadership and expertise on industry challenges and trends in packaging and containment. 

Key Points: 
  • Expert presentations and posters offer thought leadership in drug delivery innovation, patient adherence and pharmaceutical manufacturing
    EXTON, Pa., Oct. 16, 2023 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced participation in the 2023 PDA Universe of Pre-Filled Syringes and Injection Devices Conference in Gothenburg, Sweden to showcase its leadership and expertise on industry challenges and trends in packaging and containment.
  • "In the last three years, we have seen a tremendous number of changes in the industry such as increasing regulatory requirements, increasing quality standards and requests for higher performance drug packaging and devices.
  • As we celebrate our 100-year milestone, West continues to expand and advance our portfolio of high-quality drug delivery packaging and devices to provide system solutions to support increasingly more sensitive and complex molecules," says William Matakas, Vice President, Product Management, Elastomer and Container Closure Components at West.
  • West will highlight its industry expertise through several technical-focused PDA presentations and posters:
    For more information about West, please visit our website: www.westpharma.com .

Sharps Technology Issues Update Letter to Shareholders from CEO Robert Hayes

Retrieved on: 
Martedì, Aprile 4, 2023
Sterilization, Sharps, Syringe, Drug packaging, Partnership, Research, Pharmaceutical industry, Fine chemical, Nephron

NEW YORK, April 04, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, issues a shareholder update from Robert Hayes, the Company's Chief Executive Officer.

Key Points: 
  • NEW YORK, April 04, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”) (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, issues a shareholder update from Robert Hayes, the Company's Chief Executive Officer.
  • The Company completed a capital raise in February that will be used to support the manufacturing of products through our partnership with Nephron.
  • Sharps Technology's solutions overcome these challenges, providing an ideal solution for the future demand of specialty polymer-based syringe drug filling solutions.
  • I would like to thank our shareholders for their support through our transition to revenue, and we look forward to providing updates as we move ahead.

Sharps Technology Inc. to Introduce New Specialized Prefillable Syringe Systems in 2023

Retrieved on: 
Martedì, Gennaio 10, 2023
Injection, COVID, Syringe, COP, PFS, Use, Tub, COC, Glass, Safety, Silicon, Drug packaging, Sharps, Sterilization, Partnership, Workforce, Research, COVID 19, Product management, Cyclic olefin copolymer, Pharmaceutical industry, Fine chemical, Borosilicate glass

NEW YORK, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (the “Company”, "Sharps") (NASDAQ: “STSS” and “STSSW”), an innovative medical device and drug delivery Company offering patented, best-in-class syringe products, announces the advancement of the Company's specialized prefillable syringe ("PFS") system product line, which will be manufactured in collaboration with Nephron Pharmaceuticals at the Inject EZ facility in West Columbia, South Carolina.

Key Points: 
  • Sharps announced a manufacturing and research partnership with Nephron Pharmaceuticals in November 2022 that will support the manufacturing of the Company's new innovative prefillable syringe systems, which will begin in the third quarter of 2023 in South Carolina.
  • Robert Hayes, Sharps Chief Executive Officer, commented: "Following years of research and development, Sharps is now in a position to commercialize and support the future of specialty syringe drug filling technology.
  • The opportunity to advance our product and manufacturing strategy to include high value prefillable syringe products will significantly accelerate our revenue growth for 2023 and beyond.
  • This is the reason why prefillable syringe systems are considered a high growth segment of the drug packaging market.

Stevanato Group and Gerresheimer AG Present EZ-fill Smart™, a New and Innovative Ready-To-Use Vial Platform

Retrieved on: 
Martedì, Novembre 1, 2022
Biotechnology, Manufacturing, Health, Pharmaceutical, Packaging, B21, Company, Biopolymer, Administration, Health, CMOS, Automation, TCO, Efficiency, Drug packaging, Federal Executive Boards, NYSE, RTU, Ownership, Sterilization, Nest, Safety, Behavior, Group, EUR, Beauty, Board of directors, Ethylene oxide, CO2, Engineering, EZ, Biotechnology, Environment, Forward-looking statement, Solution, Stevanato Group, Cosmetics, Pharma, Fine chemical, Recycling, Gerresheimer

View the full release here: https://www.businesswire.com/news/home/20221101006001/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221101006001/en/
    Stevanato Group and Gerresheimer AG present EZ-fill Smart, a new and innovative Ready-To-Use vial platform (Photo: Business Wire)
    The companies have implemented process and product changes that can offer substantial improvements for customers.
  • The EZ-fill Smart platform leverages increased automation throughout the manufacturing process to increase productivity and reduce human errors.
  • The optimized platform features no glass-to-glass and no glass-to-metal contact, which improves quality and integrity of the vials throughout the product life cycle.
  • Together, Stevanato Group and Gerresheimer AG have obtained positive results to date and are in the validation process with this sustainable sterilization method.

Gerresheimer AG and Stevanato Group present EZ-fill Smart™, a new and innovative Ready-To-Fill Vial Platform

Retrieved on: 
Martedì, Novembre 1, 2022
Administration, Automation, TCO, RTU, Ownership, Sterilization, Safety, Beauty, Ethylene oxide, Pharma, EZ, Biotechnology, Smart, Stevanato Group, Cosmetics, Drug packaging, Medical device

The companies have implemented process and product changes that can offer substantial improvements for customers.

Key Points: 
  • The companies have implemented process and product changes that can offer substantial improvements for customers.
  • The EZ-fill Smart platform leverages increased automation throughout the manufacturing process to increase productivity and reduce human errors.
  • The optimized platform features no glass-to-glass and no glass-to-metal contact, which improves quality and integrity of the vials throughout the product life cycle.
  • The companies have redesigned the secondary packaging, which can yield a significant reduction of particle risks during customers' operations, delivering improved quality.

Gerresheimer AG and Stevanato Group present EZ-fill Smart™, a new and innovative Ready-To-Fill Vial Platform

Retrieved on: 
Martedì, Novembre 1, 2022
Administration, Automation, TCO, RTU, Ownership, Sterilization, Safety, Beauty, Ethylene oxide, Pharma, EZ, Biotechnology, Smart, Stevanato Group, Cosmetics, Drug packaging, Medical device

The companies have implemented process and product changes that can offer substantial improvements for customers.

Key Points: 
  • The companies have implemented process and product changes that can offer substantial improvements for customers.
  • The EZ-fill Smart platform leverages increased automation throughout the manufacturing process to increase productivity and reduce human errors.
  • The optimized platform features no glass-to-glass and no glass-to-metal contact, which improves quality and integrity of the vials throughout the product life cycle.
  • The companies have redesigned the secondary packaging, which can yield a significant reduction of particle risks during customers' operations, delivering improved quality.

Stevanato Group and DWK Life Sciences Sign Non-Exclusive Distribution Agreement for EZ-fill® Platform Products

Retrieved on: 
Giovedì, Ottobre 27, 2022
Science, Biotechnology, Research, Pharmaceutical, Medical Supplies, Health, Packaging, Manufacturing, Stevanato Group, Diagnosis, Biotechnology, Life Sciences Research Office, RTU, NYSE, Drug packaging, Glass, Medication, Total cost, Sale, Solution, Total cost of ownership, Duran (glass), Engineering, Applied science, Group, TCO, Laboratory, Therapy, Fine chemical, Ownership

We are pleased to welcome DWK Life Sciences as a distributor of our EZ-fill platform, said Andrea Zambon, Corporate Business Development Senior Director of Stevanato Group.

Key Points: 
  • We are pleased to welcome DWK Life Sciences as a distributor of our EZ-fill platform, said Andrea Zambon, Corporate Business Development Senior Director of Stevanato Group.
  • Through DWK Life Sciences' established, widespread and specialized network, Stevanato Group aims to broaden the reach of our EZ-fill products into the pharmaceutical ecosystem, from the laboratory to large-scale manufacturing.
  • Michele Mora, Managing Director & Chief Business Officer for DWK Life Sciences, shared: We are excited to partner with Stevanato Group to promote the EZ-fill portfolio and bring the leading RTU primary packaging platform to customers in the DWK Life Sciences global network.
  • DWK Life Sciences is the leading global manufacturer and provider of precision labware as well as primary packaging solutions for Life Science Research, Applied Sciences and Diagnostics and Pharmaceutical markets.

West Announced as Company of the Year Finalist for Global Generics and Biosimilar Awards 2022

Retrieved on: 
Giovedì, Ottobre 6, 2022
New, General manager, Standard, NYSE, Drug packaging, Patient, WST, Multimedia, Financial Times and McKinsey Business Book of the Year Award, Marketing, Company, Industry, Standard & Poor's Depositary Receipts, View, Pharmaceutical industry, West Pharmaceutical Services

EXTON, Pa., Oct. 6, 2022 /PRNewswire/ --West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced it has been shortlisted for Company of the Year for 2022 Global Generics and Biosimilar Awards, which will be announced during CPhI Worldwide in Frankfurt, Germany on November 2, 2022.

Key Points: 
  • EXTON, Pa., Oct. 6, 2022 /PRNewswire/ --West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced it has been shortlisted for Company of the Year for 2022 Global Generics and Biosimilar Awards, which will be announced during CPhI Worldwide in Frankfurt, Germany on November 2, 2022.
  • "West is honored to be shortlisted for the Global Generics and Biosimilar 2022 Company of the Year Award," said David Maier, Vice President & General Manager at West Pharmaceutical Services.
  • The Global Generics and Biosimilars Awards celebrate the greatest accomplishments and innovations across the development, authorization, marketing, and distribution of global off-patent pharmaceuticals.
  • For more information about the Global Generics and Biosimilars Awards, please visit: Generics Bulletin and Biosimilars Awards 2022 l Pharma Intelligence (informa.com)
    West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services.

SiO2 Materials Science Names Yves Steffen as Chief Executive Officer

Retrieved on: 
Giovedì, Settembre 1, 2022
University of California, Santa Barbara, University, CEO, Research, Innovation, Board, Drug packaging, Materials science, MIT, Lead, GLOBE, Silicon dioxide, Director, Customer satisfaction, Chicago (franchise), Growth, Industry, Cilag, Fine chemical, Management, Novartis, Science

AUBURN, Ala., Sept. 01, 2022 (GLOBE NEWSWIRE) -- SiO2 Materials Science today announced the Board of Directors has appointed Yves Steffen as CEO effective Aug. 1, 2022.

Key Points: 
  • AUBURN, Ala., Sept. 01, 2022 (GLOBE NEWSWIRE) -- SiO2 Materials Science today announced the Board of Directors has appointed Yves Steffen as CEO effective Aug. 1, 2022.
  • Yves Steffen is a graduate of FHBB and has more than 20 years of experience in the pharmaceutical industry in various positions.
  • Robert Abrams,Chairman of the SiO2 Board, said, "In recent years, SiO2 has successfully completed the development of a revolutionary technology for the life science industry.
  • SiO2 Materials Science is an advanced materials science corporation introducing breakthrough disruptive technology serving the biopharma, molecular diagnostic, and consumer healthcare industries.

West Announces Landmark Collaboration with Corning in Pharmaceutical Injectable Drug Delivery

Retrieved on: 
Martedì, Gennaio 25, 2022
Patient, Technology, Daikyo, Invention, Corning Inc., RD&E, Science, NYSE, Public health, View, Drug packaging, Glass, West Pharmaceutical Services, Multimedia, WST, Engineering, Design, Partnership, Patient safety, Pharmaceutical industry, Fine chemical, Drug, Corning

The new collaboration includes a multimillion-dollar investment to expand Corning's Valor Glass technology to enable advanced injectable drug packaging and delivery systems for the pharmaceutical industry with the goal of advancing patient safety and expanding access to life-saving treatments.

Key Points: 
  • The new collaboration includes a multimillion-dollar investment to expand Corning's Valor Glass technology to enable advanced injectable drug packaging and delivery systems for the pharmaceutical industry with the goal of advancing patient safety and expanding access to life-saving treatments.
  • "West and Corning have developed this exceptional collaboration to offer leading elastomer-glass system solutions for the containment and delivery of injectable medicines," said Eric M. Green, President and Chief Executive Officer, West.
  • "At West, we value the state-of-the-art products offered by Corning and are excited to build together the next generation of integrated packaging and delivery innovations."
  • West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services.